VYNE Therapeutics Inc VYNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VYNE is a good fit for your portfolio.
News
-
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
-
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
-
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
-
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $2.47
- Day Range
- $2.42–2.58
- 52-Week Range
- $1.71–8.73
- Bid/Ask
- $2.43 / $2.58
- Market Cap
- $34.26 Mil
- Volume/Avg
- 9,889 / 108,711
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 59.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.vynetherapeutics.com
Valuation
|
Metric
|
VYNE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.39 |
Price/Sales | 59.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VYNE
|
|---|---|
Quick Ratio | 12.37 |
Current Ratio | 12.73 |
Interest Coverage | — |
Quick Ratio
VYNE
Profitability
|
Metric
|
VYNE
|
|---|---|
Return on Assets (Normalized) | −56.36% |
Return on Equity (Normalized) | −70.13% |
Return on Invested Capital (Normalized) | −70.04% |
Return on Assets
VYNE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ywgvhmgls | Plbhh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hgwbgphrb | Xqtxl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ydtrscdd | Zrckhmw | $97.8 Bil | |
MRNA
| Moderna Inc | Xmrpllq | Ytnz | $38.8 Bil | |
ARGX
| argenx SE ADR | Rjbqgvmj | Zbpg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vsjtfnnrg | Qpc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hvdsqzljv | Xltvjmj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wqkdqwjr | Wrfykn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rjghhjpry | Mfsbdgn | $12.5 Bil | |
INCY
| Incyte Corp | Gvzvwcqqp | Zfnwpr | $11.5 Bil |